2013 Korean Society of Hypertension guidelines for the management of hypertension. Part III—hypertension in special situations

키워드

참고문헌 (145)

1. Verdecchia P., "Short-and long-term incidence of stroke in white-coat hypertension", Hypertension, 45, pp.203~208 (2005)
2. Verdecchia P., "The natural history of white-coat hypertension in the long term", Blood Press Monit, 10, pp.65~66 (2005)
3. Ohkubo T., "Prognosis of"masked"hypertension and"white-coat"hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study", J Am Coll Cardiol, 46, pp.508~515 (2005)
4. Alberti KG., "Harmonizing the metabolic syndrome : a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society;and International Association for the Study of Obesity", Circulation, 120, pp.1640~1645 (2009)
5. The Asia-Pacific Perspective:redefining obesity and its treatment, "International Association for the Study of Obesity.", WHO, ~ (2000)
6. Lim S., "Increasing prevalence of metabolic syndrome in Korea : the Korean National Health and Nutrition Examination Survey for 1998–2007", Diabetes Care, 34, pp.1323~1328 (2011)
7. Cha MJ., "Prevalence and clinical characteristics of metabolic syndrome in Korean hypertensive patients", J Korean Soc Hypertens, 15, pp.37~44 (2009)
8. Gami AS., "Metabolic syndrome and risk of incident cardiovascular events and death : a systematic review and meta-analysis of longitudinal studies", J Am Coll Cardiol, 49, pp.403~414 (2007)
9. Ford ES., "Metabolic syndrome and incident diabetes : current state of the evidence", Diabetes Care, 31, pp.1898~1904 (2008)
10. Cheung BM., "Development of diabetes in Chinese with the metabolic syndrome : a 6-year prospective study", Diabetes Care, 30, pp.1430~1436 (2007)
11. Mukai N., "Impact of metabolic syndrome compared with impaired fasting glucose on the development of type 2 diabetes in a general Japanese population : the Hisayama study", Diabetes Care, 32, pp.2288~2293 (2009)
12. American Diabetes Association., "Standards of medical care in diabetes 2013", Diabetes Care., 36(Suppl 1), pp.S11~S66 (2013)
13. Gress TW., "Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study", N Engl J Med, 342, pp.905~912 (2000)
14. Weycker D., "Excess risk of diabetes in persons with hypertension", J Diabetes Complications, 23, pp.330~336 (2009)
15. Celik T., "Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients", J Hypertens, 24, pp.591~596 (2006)
16. Dhakam Z., "A comparison of atenolol and nebivolol in isolated systolic hypertension", J Hypertens, 26, pp.351~356 (2008)
17. Bakris GL., "Metabolic effects of carvedilol vs metoprolol in patients with type 2diabetes mellitus and hypertension : a randomized controlled trial", JAMA, 292, pp.2227~2236 (2004)
18. Mancia G., "2013 ESH", ESC Guidelines for the management of arterial hypertension : the Task Force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC), 2013, pp.31, 1281~1357
19. Elliott WJ., "Incident diabetes in clinical trials of antihypertensive drugs : a network meta-analysis", Lancet, 369, pp.201~207 (2007)
20. Mann JF., "Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk(the ONTARGET study) : a multicentre, randomised, double-blind, controlled trial", Lancet, 372, pp.547~553 (2008)
21. Adler AI., "Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes(UKPDS 36) : prospective observational study", BMJ, 321, pp.412~419 (2000)
22. Officers ALLHAT., "Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT)", JAMA, 288, pp.2981~2997 (2002)
23. Beulens JW., "Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus : a randomised controlled trial", Diabetologia, 52, pp.2027~2036 (2009)
24. Lindholm LH., "Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE) : a randomised trial against atenolol", Lancet, 359, pp.1004~1010 (2002)
25. Yusuf S., "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators", N Engl J Med, 342, pp.145~153 (2000)
26. Lenfant C., "Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure(JNC 7) : resetting the hypertension sails", Hypertension, 41, pp.1178~1179 (2003)
27. Cushman WC., "Effects of intensive blood-pressure control in type 2 diabetes mellitus", N Engl J Med, 362, pp.1575~1585 (2010)
28. Turnbull F., "Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus : results of prospectively designed overviews of randomized trials", Arch Intern Med, 165, pp.1410~1419 (2005)
29. Beckett NS., "Treatment of hypertension in patients 80 years of age or older", N Engl J Med, 358, pp.1887~1898 (2008)
30. Whelton PK., "Sodium reduction and weight loss in the treatment of hypertension in older persons : a randomized controlled trial of nonpharmacologic interventions in the elderly(TONE). TONE Collaborative Research Group", JAMA, 279, pp.839~846 (1998)
31. Liu L., "The Felodipine Event Reduction(FEVER)Study : a randomized long-term placebo-controlled trial in Chinese hypertensive patients", J Hypertens, 23, pp.2157~2172 (2005)
32. JATOS Study Group., "Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients(JATOS)", Hypertens Res, 31, pp.2115~2127 (2008)
33. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension., "Final results of the Systolic Hypertension in the Elderly Program(SHEP). SHEP Cooperative Research Group", Jama, 265, pp.3255~3264 (1991)
34. Staessen JA., "Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe(Syst-Eur)Trial Investigators", Lancet, 350, pp.757~764 (1997)
35. Wing LM., "A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly", N Engl J Med, 348, pp.583~592 (2003)
36. Lithell H., "The Study on Cognition and Prognosis in the Elderly(SCOPE) : principal results of a randomized double-blind intervention trial", J Hypertens, 21, pp.875~886 (2003)
37. Blood Pressure Lowering Treatment Trialists C., "Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults : meta-analysis of randomised trials", BMJ, 336, pp.1121~1123 (2008)
38. Hanes DS., "The beta blockers : are they as protective in hypertension as in other cardiovascular conditions?", J Clin Hypertens(Greenwich), 3, pp.236~243 (2001)
39. Prisant LM., "Challenges for beta-blockers as first-line therapy for elderly hypertensive patients", Postgrad Med, 112, pp.34~41 (2002)
40. Whitlock G., "Body-mass index and cause-specific mortality in 900 000 adults : collaborative analyses of 57 prospective studies", Lancet, 373, pp.1083~1096 (2009)
41. Lewington S., "Age-specific relevance of usual blood pressure to vascular mortality : a meta-analysis of individual data for one million adults in 61 prospective studies", Lancet, 360, pp.1903~1913 (2002)
42. Mancia G., "Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study", Hypertension, 50, pp.299~305 (2007)
43. Law MR., "Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies", BMJ., 338, pp.b1665~ (2009)
44. Borghi C., "Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation", Am J Hypertens, 12, pp.665~672 (1999)
45. Tocci G., "Development of heart failure in recent hypertension trials", J Hypertens, 26, pp.1477~1486 (2008)
46. Turnbull F., "Effects of different blood-pressure-lowering regimens on major cardiovascular events : results of prospectively-designed overviews of randomised trials", Lancet, 362, pp.1527~1535 (2003)
47. Raphael CE., "Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure", Heart, 95, pp.56~62 (2009)
48. Rutten FH., "Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease", Arch Intern Med, 170, pp.880~887 (2010)
49. Massie BM., "Irbesartan in patients with heart failure and preserved ejection fraction", N Engl J Med, 359, pp.2456~2467 (2008)
50. Camm AJ., "Guidelines for the management of atrial fibrillation : the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC)", Eur Heart J, 31, pp.2369~2429 (2010)
51. Kirchhof P., "Comprehensive risk reduction in patients with atrial fibrillation : Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET", EHRA consensus conference, 2011, pp.106, 1012~1019
52. Camm AJ., "2012focused update of the ESC Guidelines for the management of atrial fibrillation : an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association", Eur Heart J, 33, pp.2719~2747 (2012)
53. Manolis A., "Sexual dysfunction : the 'prima ballerina' of hypertension-related quality-of-life complications", J Hypertens, 26, pp.2074~2084 (2008)
54. Arima H., "Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy : the PROGRESS trial", Stroke, 43, pp.1675~1677 (2012)
55. Ducharme A., "Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure : Assessment of Reduction in Mortality and morbidity(CHARM)program", Am Heart J, 152, pp.86~92 (2006)
56. Vermes E., "Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction : insight from the Studies Of Left Ventricular Dysfunction(SOLVD)trials", Circulation, 107, pp.2926~2931 (2003)
57. Wachtell K., "Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol : the Losartan Intervention For End Point Reduction in Hypertension(LIFE)study", J Am Coll Cardiol, 45, pp.712~719 (2005)
58. Schmieder RE., "Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade : the VALUE trial", J Hypertens, 26, pp.403~411 (2008)
59. Cohn JN., "A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure", N Engl J Med, 345, pp.1667~1675 (2001)
60. Yusuf S., "Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors : a randomised controlled trial", Lancet, 372, pp.1174~1183 (2008)
61. Yusuf S., "Irbesartan in patients with atrial fibrillation", N Engl J Med, 364, pp.928~938 (2011)
62. Tveit A., "Candesartan in the prevention of relapsing atrial fibrillation", Int J Cardiol, 120, pp.85~91 (2007)
63. Disertori M., "Valsartan for prevention of recurrent atrial fibrillation", N Engl J Med, 360, pp.1606~1617 (2009)
64. Schneider MP., "Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis", J Am Coll Cardiol, 55, pp.2299~2307 (2010)
65. Nasr IA., "Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure : a meta-analysis", Eur Heart J, 28, pp.457~462 (2007)
66. Swedberg K., "Eplerenone and atrial fibrillation in mild systolic heart failure : results from the EMPHASIS-HF(Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)study", J Am Coll Cardiol, 59, pp.1598~1603 (2012)
67. Zanchetti A., "Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis : principal results of PHYLLIS–a randomized double-blind tri", Stroke, 35, pp.2807~2812 (2004)
68. Zanchetti A., "Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis : principal results of the European Lacidipine Study on Atherosclerosis(ELSA), a randomized, double-blind, long-term trial", Circulation, 106, pp.2422~2427 (2002)
69. Ong KT., "Aortic stiffness is reduced beyond blood pressure lowering by short-term and l ong-term antihypertensive treatment : a meta-analysis of individual data in 294 patients", J Hypertens, 29, pp.1034~1042 (2011)
70. Karalliedde J., "Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering", Hypertension, 51, pp.1617~1623 (2008)
71. Shahin Y., "Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections : a meta-analysis and meta-regression of randomised controlled trials", Atherosclerosis, 221, pp.18~33 (2012)
72. Kampus P., "Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness", Hypertension, 57, pp.1122~1128 (2011)
73. Guerin AP., "Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure", Circulation, 103, pp.987~992 (2001)
74. Murabito JM., "Temporal trends in the incidence of intermittent claudication from 1950 to 1999", Am J Epidemiol, 162, pp.430~437 (2005)
75. De Buyzere ML., "Management of hypertension in peripheral arterial disease", Prog Cardiovasc Dis, 50, pp.238~263 (2008)
76. Paravastu SC., "Beta blockers for peripheral arterial disease", Eur J Vasc Endovasc Surg, 38, pp.66~70 (2009)
77. Paravastu SC., "Beta blockers for peripheral arterial disease", Cochrane Database Syst Rev, 9, pp.CD005508~ (2013)
78. Radack K., "Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials", Arch Intern Med, 151, pp.1769~1776 (1991)
79. Singer DR., "Management of hypertension in peripheral arterial disease : does the choice of drugs matter?", Eur J Vasc Endovasc Surg, 35, pp.701~708 (2008)
80. Kidney Disease : Improving Global Outcomes(KDIGO)CKD Work Group., "KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease", Kidney Int Suppl, 3, pp.151~ (2013)
81. 김세중, "고혈압 환자에서 만성 신질환의 유병율과신기능 감소의 예측인자", Kidney Research and Clinical Practice, 27(1), pp.20~27 (2008), 대한신장학회
82. 김영주, "한국인 심혈관질환의 유병률과 관련 위험인자: 2005년, 2007년 국민건강영양 조사를 바탕으로", Korean Journal of Health Promotion, 11(3), pp.169~176 (2011), 대한임상건강증진학회
83. Wheeler DC., "Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?", Kidney Int, 83, pp.377~383 (2013)
84. Chobanian AV., "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure", Hypertension, 42, pp.1206~1252 (2003)
85. Kdoqi., "KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease", Am J Kidney Dis., 49, pp.S12~S154 (2007)
86. Upadhyay A., "Systematic review : blood pressure target in chronic kidney disease and proteinuria as an effect modifier", Ann Intern Med, 154, pp.541~548 (2011)
87. Wright Jr JT., "Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease : results from the AASK trial", JAMA, 288, pp.2421~2431 (2002)
88. Ruggenenti P., "Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease(REIN-2) : multicentre, randomised controlled trial", Lancet, 365, pp.939~946 (2005)
89. Peterson JC., "Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study", Ann Intern Med, 123, pp.754~762 (1995)
90. Jafar TH., "Progression of chronic kidney disease : the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition : a patient-level meta-analysis", Ann Intern Med, 139, pp.244~252 (2003)
91. Maschio G., "Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group", N Engl J Med, 334, pp.939~945 (1996)
92. Ruggenenti P., "In chronic nephropathies prolonged ACE inhibition can induce remission : dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia", J Am Soc Nephrol, 10, pp.997~1006 (1999)
93. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration raterisk of terminal renal failure in proteinuric., "The GISEN Group(Gruppo Italiano di Studi Epidemiologici in Nefrologia)", Lancet, 349, pp.1857~1863 (1997)
94. Kidney Disease : Improving Global Outcomes(KDIGO)Blood Pressure Work Group., "KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease", Kidney Int Suppl, 2, pp.75~ (2012)
95. Boudville N., "Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease", Am J Hypertens, 18, pp.1300~1305 (2005)
96. Chen L., "Alcohol intake and blood pressure : a systematic review implementing a Mendelian randomization approach", PLoS Med., 5, pp.e52~ (2008)
97. Gelber RP., "Association between body mass index and CKD in apparently healthy men", Am J Kidney Dis, 46, pp.871~880 (2005)
98. Jones DW., "Body mass index and blood pressure in Korean men and women : the Korean National Blood Pressure Survey", J Hypertens, 12, pp.1433~1437 (1994)
99. Kosmadakis GC., "Benefits of regular walking exercise in advanced pre-dialysis chronic kidney disease", Nephrol Dial Transplant, 27, pp.997~1004 (2012)
100. Krikken JA., "Benefits of dietary sodium restriction in the management of chronic kidney disease", Curr Opin Nephrol Hypertens, 18, pp.531~538 (2009)
101. Whelton SP., "Effect of aerobic exercise on blood pressure : a meta-analysis of randomized, controlled trials", Ann Intern Med, 136, pp.493~503 (2002)
102. 윤중, "대한민국 건강 성인의 체질량지수 및 허리둘레 기준에 따른 복부 비만과 평가사구체여과율의 상관관계 - 2007년 국민 건강 영양조사 자료 중심으로 -", 대한비만학회지, 20(4), pp.202~209 (2011), 대한비만학회
103. Brenner BM., "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy", N Engl J Med, 345, pp.861~869 (2001)
104. Jafar TH., "Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data", Ann Intern Med, 135, pp.73~87 (2001)
105. Lewis EJ., "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes", N Engl J Med, 345, pp.851~860 (2001)
106. Acelajado MC., "Hypertension in the elderly", Clin Geriatr Med, 25, pp.391~412 (2009)
107. Benvenuto LJ., "Morbidity and mortality of orthostatic hypotension : implications for management of cardiovascular disease", Am J Hypertens, 24, pp.135~144 (2011)
108. Wu JS., "Population-based study on the prevalence and correlates of orthostatic hypotension", hypertension and orthostatic dizziness, 2008, pp.31, 897~904
109. Lawes CM., "Blood pressure and stroke : an overview of published reviews", Stroke, 35, pp.776~785 (2004)
110. Psaty BM., "Health outcomes associated with various antihypertensive therapies used as first-line agents : a network meta-analysis", JAMA, 289, pp.2534~2544 (2003)
111. Campbell NR., "Canadian Hypertension Education Program : the science supporting New 2011 CHEP recommendations with an emphasis on health advocacy and knowledge translation", Can J Cardiol, 27, pp.407~414 (2011)
112. Wiysonge CSBH, "Beta-blockers for hypertension" (2007), Opie LH
113. Aronow WS., "Treatment of hypertension and prevention of ischemic stroke", Curr Cardiol Rep, 6, pp.124~129 (2004)
114. Qureshi AI., "Rate of 24-hour blood pressure decline and mortality after spontaneous intracerebral hemorrhage : a retrospective analysis with a random effects regression model", Crit Care Med, 27, pp.480~485 (1999)
115. Schrader J., "The ACCESS study : evaluation of acute Candesartan Cilexetil therapy in stroke survivors", Stroke, 34, pp.1699~1703 (2003)
116. Hankey GJ., "Lowering blood pressure in acute stroke : the SCAST trial", Lancet, 377, pp.696~698 (2011)
117. "2011 Clinical guidelines for stroke in Korea", 뇌졸중진료지침%2020130322.pdf[URL]
118. Jauch EC., "Guidelines for the early management of patients with acute ischemic stroke : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2013, pp.44, 870~947
119. Larrue V., "Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European cooperative acute stroke study", Stroke, 28, pp.957~960 (1997)
120. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke., "The NINDS t-PA Stroke Study Group", Stroke, 28, pp.2109~2118 (1997)
121. Adams Jr HP., "Guidelines for the early management of adults with ischemic stroke : a guideline from the American Heart Association", American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups : the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists, 2007, pp.38, 1655~1711
122. Ohwaki K., "Blood pressure management in acute intracerebral hemorrhage : relationship between elevated blood pressure and hematoma enlargement", Stroke, 35, pp.1364~1367 (2004)
123. Anderson CS., "Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage", N Engl J Med, 368, pp.2355~2365 (2013)
124. Morgenstern LB., "Guidelines for the management of spontaneous intracerebral hemorrhage : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2010, pp.41, 2108~2129
125. PATS Collaborating Group., "Poststroke antihypertensive treatment study. A preliminary result", Chin Med J(Engl), 108, pp.8~ (1995)
126. Rashid P., "Blood pressure reduction and secondary prevention of stroke and other vascular events : a systematic review", Stroke, 34, pp.2741~2748 (2003)
127. Progress Collaborative Group., "Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack", Lancet, 358, pp.1033~1041 (2001)
128. Shores J., "Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome", N Engl J Med, 330, pp.1335~1341 (1994)
129. Elefteriades JA., "Thoracic aortic aneurysm clinically pertinent controversies and uncertainties", J Am Coll Cardiol, 55, pp.841~857 (2010)
130. Braverman AC., "Acute aortic dissection : clinician update", Circulation, 122, pp.184~188 (2010)
131. Dong JY., "Erectile dysfunction and risk of cardiovascular disease : meta-analysis of prospective cohort studies", J Am Coll Cardiol, 58, pp.1378~1385 (2011)
132. Gupta BP., "The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction : a systematic review and meta-analysis", Arch Intern Med, 171, pp.1797~1803 (2011)
133. Scranton RE., "Effect of treating erectile dysfunction on management of systolic hypertension", Am J Cardiol, 100, pp.459~463 (2007)
134. Kuklina EV., "Trends in pregnancy hospitalizations that included a stroke in the United States from 1994 to 2007 : reasons for concern?", Stroke, 42, pp.2564~2570 (2011)
135. Abalos E, "Antihypertensive drug therapy for mild to moderate hypertension during pregnancy", Cochrane Database Syst Rev, pp.CD002252~ (2007)
136. Regitz-Zagrosek V., "ESC Guidelines on the management of cardiovascular diseases during pregnancy : the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology(ESC)", Eur Heart J, 32, pp.3147~3197 (2011)
137. Excellence NIfHaC., "Hypertension in pregnancy. The management of hypertensive disorders during pregnancy" (2011)
138. Mustafa R., "A comprehensive review of hypertension in pregnancy", J Pregnancy, 2012, pp.105918~ (2012)
139. "Hypertension (CG127): clinical management of primary hypertension in adults"[URL]
140. Bellamy L., "Pre-eclampsia and risk of cardiovascular disease and cancer in later life : systematic review and meta-analysis", BMJ, 335, pp.974~ (2007)
141. McDonald SD., "Cardiovascular sequelae of preeclampsia", eclampsia : a systematic review and meta-analyses, 2008, pp.156, 918~930
142. Reckelhoff JF., "Novel mechanisms responsible for postmenopausal hypertension", Hypertension, 43, pp.918~923 (2004)
143. Staessen JA., "The epidemiology of the association between hypertension and menopause", J Hum Hypertens, 12, pp.587~592 (1998)
144. Chasan-Taber L., "Prospective study of oral contraceptives and hypertension among women in the United States", Circulation, 94, pp.483~489 (1996)
145. Turnbull F., "Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials", Eur Heart J, 29, pp.2669~2680 (2008)

관련 논문AI추천